[Hinews] SEOUL — South Korean biotechnology firm OncoCross and Seoul National University Hospital have embarked on a collaborative effort to advance drug discovery through artificial intelligence.

On July 9, the two entities signed a memorandum of understanding at the hospital, pledging to combine an AI-driven platform with clinical data to develop a precision drug discovery framework, they announced.

Under the agreement, Seoul National University Hospital will contribute prospective clinical trial support, patient datasets, and research design expertise. OncoCross will leverage its proprietary AI platform, RAPTOR AI, to identify therapeutic targets and derive drug candidates for intractable conditions such as cancer and rare disorders.

Photo: (From left) Kim Yi-rang, CEO of OncoCross, and Kim Young-tae, president of the hospital (Provided by OncoCross)
Photo: (From left) Kim Yi-rang, CEO of OncoCross, and Kim Young-tae, president of the hospital (Provided by OncoCross)


RAPTOR AI examines patient gene expression profiles and biomolecular data to precisely pinpoint disease mechanisms and expedite the selection of promising drug candidates. The technology holds significant potential for addressing cancers and rare diseases with limited treatment options.
“By combining our institutions’ expertise and resources, we can achieve substantial research progress,” said Kim Young-tae, president of Seoul National University Hospital. “We are committed to expanding public-private partnerships in precision medicine.”

Kim Yi-rang, CEO of OncoCross, described the partnership as “a pivotal step for AI-driven drug discovery grounded in clinical evidence.” She added, “Our focus will be on developing tailored therapies for diseases with few treatment alternatives.”

키워드

#온코크로스#서울대병원#AI의료#난치병#신약개발
저작권자 © Hinews 무단전재 및 재배포 금지
ad